Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study

• DOI: 10.2147/cia.s95362
• Publication Date: 2016-01-11T01:06:47Z
• Authors: Tohru Ohnuma; Aiko Toda; Ayako Kimoto; Yuto Takebayashi; Ryoko Higashiyama; Yuko Tagata; Masanobu Ito; Tsuneyoshi Ota; Nobuto Shibata; Heii Arai
• Keywords: Gastrointestinal function

This is the first clinical trial of this type in Japan, designed to analyze two important aspects Alzheimer's disease (AD) management using medium-chain triglycerides. Axona was administered for 3 months (40 g powder containing 20 caprylic triglycerides). We used an indurating, four-step dose-titration method (from 10 40 per day) 7 days before trial, and examined tolerance adverse effects intervention. also investigated its effect on cognitive function mild-to-moderate AD patients.This a intervention 22 Japanese patients with sporadic at stage (ten females, 12 males), mean age (± standard deviation) 63.9 (±8.5) years, Mini-Mental State Examination (MMSE) score, 10-25, seven were ApoE4-positive. During administration, we changes by obtaining MMSE assessment-scale scores. Intolerance serum ketone concentrations examined.The good, without severe gastrointestinal effects. did not improve our sample patients, even those ApoE4 allele. However, some ApoE4-negative baseline score ≥14 showed improvement their functions.The modified method, starting low dose Axona, decreased patients. might be effective relatively mildly affected (with lacking allele).